How Cell Communication May Unlock New Treatments for Heart Disease

2026-10-30 bio

Wageningen, Friday, 30 October 2026.
Backed by an €850,000 grant, Dr. Deli Zhang investigates how faulty internal cell communication drives heart conditions, using cross-species models to pioneer sex-specific therapies.

Targeting the Molecular Nexus in Cardiovascular Medicine

In the biomedical and healthtech domain of medicine, understanding the precise cellular mechanisms that precipitate chronic cardiovascular conditions represents one of the most critical frontiers for clinical intervention [1][2][4]. Cardiovascular disease remains the leading cause of death worldwide, with conditions like atrial fibrillation and heart failure placing an immense strain on global healthcare systems [2]. Dr. Deli Zhang, an associate professor based in Wageningen at the Human and Animal Physiology chair group within Wageningen University & Research (WUR), has secured an €850,000 Vidi grant from the Dutch Research Council (NWO) Talent Programme to interrogate a suspected common denominator linking these two conditions [1][2][3]. The funding allocation forms part of a competitive national funding round in 2026, wherein WUR researchers secured 8 out of the 109 awarded grants from an initial applicant pool of 712 researchers and 265 full proposals [6][7].

Unraveling Mitochondrial-Organelle Communication

The innovation centers on the role of mitochondrial-organelle contacts (MOCs)—specialized communication junctions within heart muscle cells responsible for orchestrating fat metabolism, regulating calcium flow, and maintaining cellular defense systems [1][4]. Under healthy conditions, these organelle contact sites facilitate efficient energetic transfers and metabolic signaling [1][2]. However, disruptions within these pathways are suspected of deregulating lipid metabolism and subverting the standard mechanical function of cardiomyocytes [1][2]. Such cellular breakdowns are particularly pronounced in aging populations and individuals affected by metabolic disorders, including type 2 diabetes and obesity [1][2][4].

Cross-Species Methodology and Structural Precision

To pinpoint whether these structural disruptions are directly causal in the onset of atrial fibrillation and heart failure with preserved ejection fraction (HFpEF), Dr. Zhang has designed a robust multi-model experimental architecture [1][2][3]. Supported by departmental infrastructure developed over seven years at Wageningen Animal Sciences alongside earlier university incentive funding, the study incorporates three distinct experimental animal models—isolated heart cells, fruit flies (Drosophila), and mice—which are integrated with detailed human tissue analyses [1][3][4]. This translational continuum is structured to identify the exact regulatory proteins governing mitochondrial contact sites, verifying whether preserving these structural interactions can actively prevent the pathological decline of cardiac tissue [3][4].

Pioneering Sex-Specific Therapies for Preventative Healthtech

A pivotal dimension of this medical innovation is its early and systematic integration of biological sex differences, analyzing how cellular mechanisms operate across male and female cardiac profiles [2][3][4]. Because disease progression and clinical manifestation often diverge significantly between men and women, identifying sex-specific metabolic pathways enables medical researchers and pharmaceutical developers to engineer more targeted therapeutic and preventative strategies [2][4]. By decoding these shared internal signaling breakdowns, Dr. Zhang’s biomedical research provides foundational insights that can inform future healthtech diagnostics and therapeutic interventions, lowering long-term clinical burdens by intercepting cardiovascular degeneration before irreversible failure occurs [1][2][4].

Bronnen

Cardiovascular research Healthtech innovation